G
Guanghui Gao
Researcher at Tongji University
Publications - 86
Citations - 2497
Guanghui Gao is an academic researcher from Tongji University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 24, co-authored 76 publications receiving 1637 citations. Previous affiliations of Guanghui Gao include Soochow University (Suzhou).
Papers
More filters
Journal ArticleDOI
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
Fengying Wu,Jue Fan,Yayi He,Anwen Xiong,Jia Yu,Yixin Li,Yan Zhang,Wencheng Zhao,Fei Zhou,Wei Li,Jie Zhang,Xiaosheng Zhang,Meng Qiao,Guanghui Gao,Shanhao Chen,Xiaoxia Chen,Xuefei Li,Likun Hou,Chunyan Wu,Chunxia Su,Shengxiang Ren,Margarete Odenthal,Reinhard Buettner,Nan Fang,Caicun Zhou +24 more
TL;DR: In this paper, the authors analyzed 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and presented the large scale, single cell resolution profiles of advanced NSCLCs.
Journal ArticleDOI
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li,Shengxiang Ren,Xuefei Li,Yongsheng Wang,David Garfield,Songwen Zhou,Xiaoxia Chen,Chunxia Su,Mo Chen,Peng Kuang,Guanghui Gao,Yayi He,Lihong Fan,Ke Fei,Caicun Zhou,Gerald Schmit-Bindert +15 more
TL;DR: In this article, miR-21 was found to be involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway.
Journal ArticleDOI
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Yan Wang,Tao Jiang,Z. Qin,J. Jiang,Q. Wang,Shuo Yang,Christopher J. Rivard,Guanghui Gao,Terry L. Ng,Megan M. Tu,Hui Yu,Hongbin Ji,Caicun Zhou,Shengxiang Ren,Shengxiang Ren,Jun Zhang,Paul A. Bunn,Robert C. Doebele,D.R. Camidge,Fred R. Hirsch +19 more
TL;DR: Pyrotinib showed activity against NSCLC with HER2 exon 20 mutations in both patient-derived organoids and a PDX model and showed promising efficacy in the clinical trial.
Journal ArticleDOI
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials
Guanghui Gao,Shengxiang Ren,Aiwu Li,Jianfang Xu,Qinghua Xu,Chunxia Su,Jian Guo,Qin-Fang Deng,Caicun Zhou +8 more
TL;DR: Comparing with first‐line chemotherapy, treatment of EGFR‐TKI achieved a statistical significantly longer PFS, higher ORR and numerically longer OS in the advanced NSCLC patients harboring activated EGFR mutations, thus, it should be the first choice in the previously untreated NSClC patients with activated EG FR mutation.
Journal ArticleDOI
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou,Xingya Li,Qiming Wang,Guanghui Gao,Yiping Zhang,Jianhua Chen,Yongqian Shu,Yanping Hu,Yun Fan,Jian Fang,Gongyan Chen,Jun Zhao,Jianxing He,Fengying Wu,Jianjun Zou,Xiaoyu Zhu,Xiang Lin +16 more
TL;DR: Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with HER2-mutant NSCLC in a prospective, multicenter, open-label, single-arm, phase II study.